Compare COFS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COFS | MYGN |
|---|---|---|
| Founded | 1898 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 443.5M | 429.7M |
| IPO Year | 1995 | 1996 |
| Metric | COFS | MYGN |
|---|---|---|
| Price | $29.54 | $5.35 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $36.00 | $8.06 |
| AVG Volume (30 Days) | 82.5K | ★ 1.2M |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | ★ 15.25 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | $139,099,000.00 | ★ $771,400,000.00 |
| Revenue This Year | $21.87 | $7.19 |
| Revenue Next Year | $4.47 | $5.64 |
| P/E Ratio | $28.18 | ★ N/A |
| Revenue Growth | ★ 22.14 | 2.33 |
| 52 Week Low | $24.89 | $3.76 |
| 52 Week High | $33.58 | $11.44 |
| Indicator | COFS | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.46 | 55.17 |
| Support Level | $29.57 | $4.82 |
| Resistance Level | $30.73 | $5.67 |
| Average True Range (ATR) | 0.93 | 0.40 |
| MACD | 0.04 | 0.14 |
| Stochastic Oscillator | 76.57 | 72.98 |
ChoiceOne Financial Services Inc is a full-service banking institution. It is engaged in the business of providing personal and business banking solutions, borrowing solutions, and treasury notes and bonds services. The bank's product and services portfolio consist of time, savings and demand deposits, safe deposit services, automated transaction machine services, commercial and consumer loans, commercial lending to business, industry, agricultural, construction, inventory, and real estate categories. Its primary market area is Kent, Muskegon, Newaygo, and Ottawa counties in western Michigan, and Lapeer, Macomb, and St. Clair counties in southeastern Michigan in the communities where the Bank's respective offices are located.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.